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Abstract
One in three people in the world is infected with Mycobacterium tuberculosis, and 10% of 
infected individuals will develop the disease at any time in their lifetime. Today, despite 
the advances in diagnosis and treatment, tuberculosis (TB) remains as one of the big-
gest challenges in global public health, and low and middle-income countries are the 
most affected. The risk for developing the disease depends on endogenous, exogenous, 
and environmental factors. Among the most relevant conditions that could precipitate 
TB development are those that affect the host-immune response. HIV infection increase 
about 20 times the risk of TB, and other more common conditions, such as diabetes mel-
litus, malnutrition, and smoking, also contribute in a big way to the TB pandemic. Global 
TB control programs in order to achieve the disease control objectives must integrate 
strategies that have a direct impact on risk factors, not only at an individual level but also 
on a public health policy level. Here, we review some of the most important risk factors 
for the development of TB, as one of the most relevant ways for TB control.
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1. Introduction
Tuberculosis (TB) is a bacterial infectious disease caused by Mycobacterium tuberculosis com-
plex organisms, it is an airborne-transmitted condition pathologically characterized by a nec-
rotizing granulomatous response (Figure 1) that involves the lungs in 80% of cases, however 
any organ can be affected [1]. This disease probably emerged about 70,000 years ago, along 
with the modern-human being’s migration from Africa [2]. An estimated of 1 billion people 
have died of TB in the last two centuries, and now represents one of the biggest public health 
problems worldwide [3].
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
One third of world population is latently infected with M. tuberculosis, but only 10% of 
infected people will develop active disease during their live, half during the first 2 years after 
infection, and the remainder at any moment of their lifetime [4]. In most infected individuals, 
the progression is contained by the immune system. In 2013, an estimated 9 million new TB 
cases were reported globally, equivalent to 126 cases per 100,000 population, with more than 
60% of the ill people living in 22 countries (considered as high-burden countries). However, 
according to WHO estimations during the same year around 3.3 million cases were missed 
(not reported or undiagnosed), accounting for a detection rate of only around 64%. The global 
HIV-coinfection proportion was 13% (1.1 million people), and HIV-associated TB deaths 
accounted for 25% of the total number of TB deaths [5].
The pathogenic mechanisms that determine active-TB progression are a multiple-stage game 
before and after the infection event, where the host-immune response integrity is one of the 
most relevant performers [6]. The infected individual may either rapidly progress to disease 
(primary progressive disease), may develop a particular status called latent TB infection, or 
may be able to kill the organism [7]. The occurrence of one of these scenarios depends on the 
determinants of host-immune response and the infection-stage in each individual. Most of the 
immune determinants that drive this pandemic constitute risk factors, which could be modi-
fied in order to impact positively on global TB control.
Among the relevant risk factors for TB, HIV infection is the most important, however, at the 
population level, diabetes mellitus (DM), malnutrition, tobacco smoking, and even immuno-
suppressive drugs, which are present in a larger section of the population than HIV infection, 
can represent a bigger impact on TB epidemiology [8, 9]. This chapter aims to summarize 
some of the most relevant risk factors for TB, focusing on general interventions for disease 
control.
Figure 1. This illustration represents a tuberculous granuloma at its most basic way. It is a compact, dynamic and 
organized aggregate of epithelioid macrophages, and these cells usually fuse into multinucleated giant cells or 
differentiate into foam cells characterized by lipid accumulation. M. tuberculosis is usually present in the central necrotic 
area in which dead and dying cells are present. Many other cell types are also infiltrating the granuloma (neutrophils, 
dendritic cells, B and T lymphocytes, natural killer cells and fibroblasts) (original illustration by Jurado LF).
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2. Human immunodeficiency virus and TB coinfection
HIV coinfection is the most important immunosuppressive condition for developing active 
TB [10]. HIV infection substantially increases the possibility of TB reactivation from latent 
infection [11], and in the same way contributes to rapid TB progression after infection with 
M. tuberculosis [12, 13]. According to WHO estimations, people living with HIV (PLWHIV) 
latently TB-infected, have a 26-fold-higher risk of disease progression than those with no HIV [14]. 
Thus, HIV and TB coinfection configure a lethal synergy, where HIV markedly increases sus-
ceptibility for TB and exacerbates the severity of the disease, while TB accelerates HIV replica-
tion and its associated morbidity and mortality outcomes [10, 15].
In 2012, 34.5 million people were living with HIV worldwide [16]. This epidemic affects every 
country in the world, but the disease burden is highest in developing countries, among which 
the sub-Saharan Africa region is the most affected, where 69% of worldwide infected people 
live [16]. Due to the advances on therapy and prevention strategies, deaths related to HIV 
have decreased substantially over the past years, but reductions in TB-related deaths have 
not kept pace, a sample of this, in 2014 TB overpasses HIV as the leading cause of global 
infectious-related mortality [10].
Among 9.6 million new TB cases reported worldwide in 2014, 12% (1.2 million) were also HIV 
positive, and of the 1.5 million who died from TB, 33% (4,00,000) were HIV coinfected, thus TB 
constitutes main mortality cause in PLWHIV [14]. Evidently, the TB incidence and TB-related 
mortality are strengthened by HIV burden and represent a real public health challenge in 
areas where HIV and poverty coexist [10].
It is clear that antiretroviral therapy (ART) reduces rapidly and substantially TB incidence in 
PLWHIV, and this is true both in high and low endemic TB areas [17–19]. Nevertheless, even 
in people under ART, the risk of TB remains high compared with the general population. For 
HIV-negative people with latent TB infection (LTBI), the lifetime risk of developing TB rounds 
5–10% [20, 21], but in the case of PLWHIV the annual risk of reactivation is 3–16% [22], with 
the higher risk of TB disease almost immediately after HIV infection, even with normal CD4 
cell levels [10].
The immunologic control of TB is an intricate phenomenon that involves multiple pathways, 
cellular lines, and host-pathogen interactions [6]. In PLWHIV, macrophages present a pheno-
type with altered activity of molecules like iNOS and TNFα, which is reflected as incapacity 
for M. tuberculosis killing [23]. The histopathologic features in PLWHIV who develop TB, cor-
relate and depend on the level of immunosuppression, individuals with apparently normal 
immune response present typical granulomas (Figure 1), these well-structured aggregates 
may break down, giving way to cavitary disease and bacilli expectoration, but as the immu-
nodeficiency advance, granulomas are poorly formed or even absent, so the cavitary form is 
less frequent, with sputum smears likely negative [24].
In like manner that HIV infection increases the TB risk and its related complications, TB also 
affects HIV infection outcomes. In a study conducted by Lawn et al. [25], HIV patients on 
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ART who develop TB, presented more alterations on CD4 counts than individuals who never 
developed TB. Studies have shown that TB associates with rapid progression to AIDS and 
higher death risk [26, 27] and TB also appears to induce viral replication and viral diversity 
via up regulating the host-immune response [15, 28].
As we previously exposed, PLWHIV have the higher risk of progression from latent to active 
TB disease, this possibility can be reduced using two fundamental strategies: adequate ART 
and prophylactic LTBI treatment [19, 29], studies support the use of both strategies even in 
patients with high CD4 counts [33]. Thus, it is highly recommended to provide ART to all 
HIV-infected people irrespective of CD4 count [17].
Considering the risk, all PLWHIV should be screened using TST for LTBI at the time of HIV 
diagnosis [30]. Once a patient has a positive result for LTBI, active disease must be ruled 
out, and preventive therapy offered. Among the preventive therapy options, two of the most 
accepted are: daily isoniazid 5 mg/kg (maximum 300 mg) for 9 months plus pyridoxine sup-
plementation or once a week rifapentine plus isoniazid (900/900 mg) for 3 months (12 total 
doses) [31, 32]. These regimens can be used with nucleoside reverse transcriptase inhibitors 
and efavirenz [33], rifapentine cannot be administered together with protease inhibitors, but 
it could be offered with raltegravir [34].
3. Diabetes mellitus and TB comorbidity
The worldwide rising in type II diabetes mellitus prevalence constitutes one of the biggest 
challenges for TB control [35]; in fact, nowadays there are more individuals living with DM-TB 
comorbidity that HIV-TB coinfection [36]. This association has been recognized historically 
[37]; however, it became less evident in the 1950s, in part due to the development of insulin 
therapy for a DM and antibiotics for TB [35]. Since 1980 as the DM pandemic (prevalence 
increasing >20% in three decades) was more evident, many papers on the DM-TB association 
began to reemerge [35].
As a result of a sedentary lifestyle, changes in diet, population aging, and urbanization, the 
global DM prevalence by 2000 was 171 million people, and is predicted that this number 
reaches 642 million in 2040, considering that 80% of DM population live in low- and middle-
income countries, where the TB situation is worst [38].
Biological evidence supports that DM induces a direct impairment on innate and adaptive 
immune responses, increasing TB susceptibility [8]. However, the DM case differs from 
other causes of immunological impairment like HIV infection or malnutrition, because DM 
response is more dysfunctional rather than dismissing, characterized by excessive and/or 
delayed responses against M. tuberculosis [39]. Investigations in humans and animals have 
shown altered production of cytokines as INF-𝛾 and IL-17 that affects the T-cell immune 
response [40] and reduced chemotaxis of neutrophils [41].
According to multiple studies, at an individual level, people with DM have three times more 
risk of developing TB, and two-fold increase in adverse TB therapy outcomes [8]. A system-
atic review of 13 studies reported that DM increases three times the risk of developing TB, 
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(relative risk 3.11; 95% IC 2.27 – 4.26) [42], notwithstanding, this epidemiological aspect is the 
best characterized in the DM-TB association, a wide variation between studies is observed, 
with risk ratios around 0.99 and 7.83 [39], which evidences the difficulty of studying DM-TB 
relation, in part due the heterogeneity in the prevalence and other sociodemographic and 
cultural features of DM and TB in each part of the world. Besides, in the case of DM, the 
presence of other host characteristics as smoking, malnutrition, micro- and macrovascular 
compromise, can synergize and increase the TB risk [43].
The relevance of the DM-TB comorbidity is higher in low and middle-income countries, 
where both diseases are more prevalent. In fact, as reported by the WHO, of the 10 countries 
with more DM patients worldwide, six are also classified as high burden countries for TB 
(China, India, Brazil, Bangladesh, Indonesia, and Russia) [44]. During the last years, studies 
have marked differences in DM’s frequency among patients with TB, from 36% in Mexico to 
40 and 56% in the Pacific Islands and India, respectively [45–48].
Talking about the impact of DM in TB control, at the population level, the general attributable 
risk is 10–20%, and also a variation between different populations is observed, even in the 
same country, for example, in the United Kingdom, the general population risk rounds 10%, 
but rises 20% for Asian males [49], in countries like Mexico, where DM is endemic the general 
attributable risk is about 20% [50], and in the EU – Mexico border, 51% of the TB patients who 
are 35–60 years-old also have DM [45]. And even though the DM confers a notably lower risk 
compared with HIV, in certain populations where the HIV prevalence is low, the contribution 
of DM is more important than HIV infection [51].
Recently, an elegant study by Pan et al. [52], using models of dynamic TB transmission, esti-
mated the potential effects of DM on TB epidemiology in 13 high burden countries, found that 
interrupting the rise in DM incidence, could prevent 6 million cases and 1.1 million deaths 
due TB in 2 decades. These findings show how beneficial for TB control would be an integral 
intervention on DM occurrence.
It is known that DM modifies the clinical presentation, disease-course and TB prognosis, and 
represents a risk factor for treatment-failure [35]. DM-TB patients (versus TB patients without 
DM) are more prone to develop sputum smear-positive TB, pulmonary TB (versus extrapul-
monary), cavitary (versus noncavitary) at the moment of diagnosis, and in DM-TB patients 
the sputum smear conversion takes more time [53]. Mycobacterium tuberculosis infection 
induces a strong cell-mediated immune response that triggers a granulomatous response, 
which, according to recent investigations is a double-edged sword for the host [54], because 
although this phenomenon initially limits bacilli replication, the growing and rupture of these 
structures into the airways, facilitates not only the cavitary form of the disease but also, its 
sputum smear-positive presentation [44]. These findings, allows to postulate that DM-TB 
patients would be more infectious that TB-only patients.
Evidence from observational studies, have shown that DM comorbidity is related to adverse 
TB outcomes, as delays in sputum conversion, increased risk for treatment failures, relapse, 
death, and even reinfection [55]. Baker et al. [56] in a meta-analysis of recent DM-TB associa-
tion studies found that the odds of dying of TB, or any other reason, was 2-fold higher [RR, 
1.89; 95% CI, 1.52–2.36], and this risk rise to 4.95, when data was adjusted for age and potential 
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confounders, the same study also calculated a 4-fold risk of relapse for DM-TB individuals 
versus TB-only patients.
Considering this, the World Health Organization has argued that DM is a reemerging and 
an important risk factor for TB, which needs programmatically routed efforts to positively 
impact on TB control [57].
4. Malnutrition and TB
For centuries, the association between malnutrition and TB has been recognized. Nutritional 
supplementation with protein-rich foods for sick people was reported since the ancient 
Greece [58]. A classic report from Denmark reports high TB rates during the First World War, 
once food supplies were restored, TB rates were drastically reduced, while persisting high in 
neighboring countries where shortages persisted [59].
During the pre-chemotherapy era, the only treatment offered to TB patients consisted in a 
nutritional plan, resting, and sun therapy. The pharmacological advances of the past cen-
tury, with the development of streptomycin and isoniazid, replaced nutritional therapy as the 
focus of anti-TB treatment, however, considering the high rates of TB in areas where malnutri-
tion is endemic, in the last decades, an interest in this association has reemerged [60].
According to estimations of the United Nations, by 2015 there were 795 million undernour-
ished, comprising around 13% of the population of low- and middle-income countries, with 
the highest prevalence in Sub-Saharan Africa and Southern Asia [61]. In the developing coun-
tries, protein-calorie malnutrition is the most frequent form of under nutrition; however, 
specific micronutrient deficiencies are also common [60]. In addition, the advent of climate 
change, population growth, the HIV pandemic, and economic inequality, have originated a 
negative impact on food and nutritional insecurity, and malnutrition rates, constituting one 
of the most challenging public health problems worldwide [43]. The general way to epidemio-
logically defining malnutrition is the body mass index (BMI), and malnutrition constitutes a 
well-known risk factor not only for TB development, but also for poor response to antibiotic 
treatment and TB-related complications [59].
A biologically plausible association between TB and malnutrition clearly exist; animal studies 
have shown that PCM affects the immune mechanisms for TB control, among the impaired pro-
cesses are the TNF, iNOS, and interferon γ production; it is also known that this phenomenon 
can be reversed thought protein supplementation [59, 62]. Active TB and HIV infection induce a 
14 and 30% increment in the resting metabolic rate, respectively, which reflects the physiological 
cost of the immunologic mechanisms that are activated during these diseases [63]. These condi-
tions aggravate even more the patient-immune impairment in the malnutrition setting [64].
Considering this, is essential that all newly diagnosed individuals with TB have a complete 
nutritional evaluation, and in the cases with a BMI under 18.8 a micro and macronutrients 
supplementation at least for the first 2 months of treatment, is strongly recommended [65]. 
Historical evidence supports the beneficial impact of social interventions, such as improving 
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housing conditions and nutritional interventions on TB epidemiology, therefore a well-planned 
wide intervention would impact positively on TB control.
5. Anti-TNF treatment and TB
People with immune-mediated inflammatory diseases, such as rheumatoid arthritis, systemic 
erythematous lupus, ankylosing spondylitis, inflammatory bowel disease, etc., also represent 
a high-risk group for developing TB, and this risk is even higher when they are treated with 
tumor necrosis factor α (TNF α) – antagonist [66, 67].
Different cells produce TNF, including macrophages, T cells, fibroblast, and keratinocytes. 
TNF is a molecule with a wide functional spectrum, plays a key role in immune response to 
infections, cancer etiology, and the physiopathology of many immune-mediated disorders 
[67]. It is also known that is important in the immune response against intracellular bacteria, 
and the physiology and integrity of granulomatous (Figure 1) TB-related response during 
LTBI, therefore its antagonism associates with TB progression [6].
During the past two decades, TNF antagonists have been successfully used for the treatment 
of inflammatory diseases, when patients do not respond to conventional therapy [67]. In 
the United States, using national surveillance data, found that TB incidence in AR patients 
increased from 6.2 per 100,000 people to 144 per 100,000 in who received infliximab and 35 per 
100,000 for etanercept-treated individuals [69]. A Spanish study collected data from 71 infor-
mation centers, with a total of 1540 patients receiving infliximab, estimated a TB incidence 
in 1893 per 100,000 people, compared with a previous reports incidence of 21 per 100,000 in 
the general population and 95 per 100,000 in AR patients without TNF treatment [70]. An 
important proportion of extrapulmonary TB is observed, and several reports have attributed 
differential risk for each TNF antagonist [68].
Most of the active TB cases in individuals treated with TNF antagonist correspond to reactiva-
tion from LTBI, when this occurs, generally happen concomitantly with the initiation of the 
TNF antagonist, nevertheless, also cases with long treatment periods, have been reported [67]. 
Therefore, screening for LTBI before any TNF inhibitor treatment initiation is mandatory, 
here, as in the case of other immunosuppressive conditions, such as HIV infection, both TST 
and IGRAs assays could be used, nowadays, there is not sufficient evidence to recommend 
one method over another, and considering this, an expert consensus, suggest using IGRAs or 
TST in people without history of BCG vaccination [71].
Once a patient has a positive result for LTBI, active disease must be ruled out, and preven-
tive therapy offered. Among the preventive therapy options, two of the most accepted are: 
daily isoniazid 5 mg/kg (maximum 300 mg) for 9 months plus pyridoxine supplementation 
or a combined regimen with isoniazid and rifampicin for 3 months [69]. Multiple recom-
mendations on delay periods between LTBI preventive chemotherapy and TNF antagonist 
have been proposed, ranging from starting both concurrently, to waiting even a month after 
finishing LTBI prophylaxis [67, 68], these decisions must always consider the patients clinical 
status.
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In the cases when active TB is diagnosed during TNF antagonist treatment, there is no evi-
dence that the length of anti-TB therapy needs to be prolonged, and evidence regarding the 
time for restarting TNF antagonist therapy is limited [72]; however, some international guide-
lines recommends starting TNF inhibitor at least when initial anti-TB phase is completed, 
while others recommend waiting until completing all TB treatment [68].
6. Smoking, alcoholism and TB
Globally, there are more than 1.5 billion smokers, the majority live in low- and middle-income 
countries, where, in addition, the per capita tobacco consumption is increasing continuously 
[73]. The prolonged exposure to tobacco smoke may directly affect the respiratory and sys-
temic immune function, which can impair alveolar macrophage function by decreasing its 
TNF production [74]. Therefore, it is considered that smoking has an impact upon the suscep-
tibility to TB development.
There is growing evidence that correlates smoking with TB disease; a cross-sectional study 
in Shanghai compared heavy smokers with nonsmokers and found that the odds of smok-
ers were 2.2 times higher than nonsmokers [75]. The risk also seemed to be influenced by 
the amount smoked, and a study from the United States found that the greatest risk was for 
people who smoked for more than 30 years [76].
At a population level, exposure to tobacco smoke has a relevant impact on TB epidemiology; 
a Chinese modeling-study suggested that a complete cessation of smoking in that country 
would reduce the estimated TB incidence between 14 and 52% [77]. Considering this situa-
tion, smoking cessation as a public health strategy is a global priority.
Alcohol is one of the most abused substances in the world. By 2005 among people aged 
15 years and older, the annual per capita consumption was 6 l [78] with the highest rates in 
high-income countries. Alcohol abuse is an important cause of immunological impairment, 
often associated with smoking and malnutrition, increasing its impact on public health [8].
There is considerable evidence to support the association between alcohol abuse and TB, even 
if it is independent of smoking [79]. Studies have shown that excessive alcohol consumption 
increases the risk of active TB development and other respiratory infections, a meta-analy-
sis estimated a combined risk of 2.9 for active TB developing [25]. Studies have also shown 
higher rates of MDR-TB, TB relapse, and treatment failure in alcohol abusers [8].
7. Genetic susceptibility
Historically, infectious disease research has considered TB as a purely infectious condition. 
During the last decades, increasing evidence suggest that TB reflects the human genetic 
vulnerability [80]. Nevertheless, the precise significance and behavior of the genetic factors 
involved remains widely unknown, in part due to the complex game of infection, latency, and 
disease, which characterizes TB.
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Recent findings have exposed two major principles: there is a main locus that controls most 
of the TB-resistance phenotypes, and there is evidence that severe forms of childhood TB 
are directly related with single-gene inborn errors (Mendelian Inheritance), meanwhile 
genetic association studies of adulthood-TB has shown limited success and reproducibility 
[81]. Clinical and epidemiological studies conducted since the past century has provided 
evidence that each step during infection and disease is strongly influenced by host genetic 
factors [82].
Familial studies aimed to investigate the human susceptibility to M. tuberculosis infection, 
have used TST and IGRAs responses as quantitative traits of resistance. Its results suggest 
that the initial infection-related events mostly depend on the IFNγ and TNF1 and its related 
cellular functions [83]. In regard to severe primary TB forms, during the last two decades, 
germ line mutations in seven autosomal and in two X-linked genes have been discovered in 
particular patients, further analysis have shown that these mutations result in an impairment 
of IFNγ- and IL12-related immunity [80, 84, 85].
Many questions of this field remain unanswered, the identification of the genetic variants 
underling the stages and forms of TB is critical for understanding TB pathogenesis. These 
findings could represent a formidable opportunity in the definition of prevention strategies, 
optimization of vaccines, the development of novel treatments and therefore TB control.
8. Final considerations
After this short review, it makes evident that a risk factor approach for TB control would have 
a huge impact on disease burden worldwide. Identification of LTBI along with prophylac-
tic therapy and active disease surveillance constitute the most important tools for reducing 
the risk of TB and achieve favorable outcomes, especially in the high-risk groups previously 
described.
Over the last decades, the understanding of TB epidemiology behavior in the country, and at 
global level, has changed from an “exposure to bacteria” vision to a phenomenon where the 
host susceptibility plays a crucial role. Even although, HIV coinfection is the most potent risk 
factor, globally the most frequent conditions impacting on people immune function include 
malnutrition, Diabetes, smoking, and immunosuppressive drugs, and while at the individ-
ual level, these factors cause an apparently mild immunological impairment, its cumulative 
importance in a community needs much more attention. So, it is imperative for clinicians, 
researchers and policy makers, a better consideration, and understanding of these conditions 
as drivers of TB epidemiology, developing in this way more integrative strategies that could 
have a bigger impact on TB control.
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